Experience with B cell depleting DMT

US - 56 POMS

62% reduction in relapses when compared with first-line injectables follow-up 24 m Decrease in ARR

SWEDISH POMS cohort- 14 patients, Median period of 23.6 months, a stable disease was observed in 13/14 patients (93%)

Side effects were similar with infusion-induced reactions being the most common, followed by rashes and fewer

Krysko KM, Graves JS, Rensel M, Weinstock-Guttman B, Rutatangwa A, Aaen G, et al. Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis. Ann Neurol. 2020;88(1):42–55 ; Salzer J, Lycke J, Wickstrom R, Naver H, Piehl F, Svenningsson A. Rituximab in paediatric onset multiple sclerosis: a case series. J Neurol. 2016; Bibino C et al, Eur J Paediatr Neurol 2023 Jan 27;43:1-5